Stockscreener 앱 받기
6.01
9.27%
0.51
전일 마감가:
$5.50
열려 있는:
$5.39
하루 거래량:
75,388
Relative Volume:
1.58
시가총액:
$95.88M
수익:
-
순이익/손실:
$-33.82M
주가수익비율:
-0.2349
EPS:
-25.5891
순현금흐름:
$-66.04M
1주 성능:
-22.85%
1개월 성능:
-26.53%
6개월 성능:
+30.65%
1년 성능:
-20.08%
1일 변동 폭
$5.15
$6.18
1주일 범위
$4.7524
$7.48
52주 변동 폭
$3.3419
$11.45
Elicio Therapeutics Inc Stock (ELTX) Company Profile
명칭
Elicio Therapeutics Inc
전화
(857) 209-0050
주소
451 D STREET, 5TH FLOOR, BOSTON
ELTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ELTX
Elicio Therapeutics Inc
|
6.01 | 95.88M | 0 | -33.82M | -66.04M | -25.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Elicio Therapeutics Inc 주식(ELTX)의 최신 뉴스
Elicio Therapeutics (ELTX) Upgraded to Buy: Here's What You Should Know - MSN
Is Elicio Therapeutics, Inc. (ELTX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Elicio Therapeutics Advances Cancer Immunotherapy Pipeline - TipRanks
Elicio signals delay in mid-stage cancer vaccine study; shares slump - TradingView
Elicio Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Elicio Therapeutics, Inc. SEC 10-K Report - TradingView
Elicio Therapeutics Reports 2024 Financial Results and Provides Corporate Updates - GlobeNewswire
Elicio's Latest Financial Results Reveal Key Clinical Milestones and 28.9-Month Survival Data - Stock Titan
(ELTX) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com
Elicio Therapeutics Names Preetam Shah CFO -March 24, 2025 at 08:17 am EDT - MarketScreener
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer - GlobeNewswire
Elicio Therapeutics Hires CFO From Cidara Therapeutics - MarketWatch
Elicio Therapeutics Appoints New Chief Strategy and Financial Officer - TipRanks
Elicio Therapeutics appoints new CSFO amid clinical trials - Investing.com
Strategic Move: Elicio Strengthens Leadership Team Ahead of Crucial Phase 2 Trial Results - Stock Titan
Elicio Therapeutics, Inc. (NASDAQ:ELTX) surges 13%; individual investors who own 49% shares profited along with insiders - simplywall.st
The hottest cancer vaccine companies you should know about - Labiotech.eu
With 36% ownership, Elicio Therapeutics, Inc. (NASDAQ:ELTX) insiders have a lot at stake - Yahoo Finance
Objective long/short (ELTX) Report - Stock Traders Daily
How to Take Advantage of moves in (ELTX) - Stock Traders Daily
Clal Biotech Completes Elicio Divestment and Initiates Loan Repayment - TipRanks
Knoll Capital Management, LLC Acquires Significant Stake in Elic - GuruFocus
Why These 15 Healthcare Stocks Are Skyrocketing So Far In 2025 - Insider Monkey
Why Elicio Therapeutics Inc (ELTX) Is Skyrocketing So Far In 2025 - Insider Monkey
Elicio Therapeutics secures $10 million in direct offering - MSN
Elicio: Lymph Node Binding With ELI-002 Could Lead To Substantial 1st Half 2025 Data - Seeking Alpha
Elicio Therapeutics Announces $10.0 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules - GlobeNewswire
Elicio Therapeutics Advances with New Clinical Updates - TipRanks
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
FDA Supports Registrational Strategy for ELI-002 in KRAS-Driven Cancers - Targeted Oncology
Elicio Therapeutics Reaches Alignment with FDA on ELI-002 Registrational Strategy - The Manila Times
Elicio Therapeutics Secures FDA Support for ELI-002 Cancer Therapy Phase 3 Strategy - StockTitan
(ELTX) Investment Report - Stock Traders Daily
Why INNOVATE Shares Are Trading Higher By Over 19%; Here Are 20 Stocks Moving Premarket - Benzinga
Why Versus Systems Shares Are Trading Higher By Around 71%; Here Are 20 Stocks Moving Premarket - Benzinga
Serina Therapeutics Appoints Former Jazz Pharmaceuticals Finance Executive Karen Wilson to Board - StockTitan
Pre-market Movers: SANA, SLDB, JSPR, DRIO... - RTTNews
Trading (ELTX) With Integrated Risk Controls - Stock Traders Daily
Elicio Therapeutics Advances ELI-002 and Secures Funding - Yahoo Finance
Elicio reports promising cancer vaccine trial results By Investing.com - Investing.com Canada
Elicio Therapeutics Presents Updated Results from ELI-002 - GlobeNewswire
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO - The Bakersfield Californian
Elicio Therapeutics Presents Updated Results from ELI-002 Phase 1 AMPLIFY-201 Study at ESMO Immuno-Oncology Congress 2024 - Business Upturn
(ELTX) Investment Analysis and Advice - Stock Traders Daily
Elicio completes phase 2 enrollment for cancer vaccine By Investing.com - Investing.com Canada
Elicio completes phase 2 enrollment for cancer vaccine - Investing.com India
Elicio Therapeutics Announces Completion of Phase 2 AMPLIFY-7P Study Enrollment - GlobeNewswire
Elicio Therapeutics Completes Phase 2 Trial Enrollment for Pancreatic Cancer Treatment - StockTitan
SEC Form 424B3 filed by Elicio Therapeutics Inc. - Quantisnow
Elicio Therapeutics: Q3 Earnings Snapshot - mySA
Elicio Therapeutics Inc (ELTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.01%
자본화:
|
볼륨(24시간):